Idelalisib FDA Approved to Combat Three Blood Cancers


Idelalisib is FDA Approved Gilead has announced the July 23, 2014 Idelalisib FDA approved news. The Idelalisib (or the brand name Zydelig) approval was long awaited, to combat three forms of blood cancer. The FDA extended a nod to this powerful drug, which is estimated to earn roughly 1.2 billion dollars by the year 2020. Approved to treat three type of B-cell blood cancer, Idelalisib is effective for relapsed follicular B-cell non-Hodgkin lymphoma, relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma. As a formidable first-in-class PI3k inhibitor Idelalisib will be administered along with Rituximab for patients fighting refractory chronic lymphocytic leukemia. While there is a slight risk of serious toxicities, the majority of patients had common adverse reactions that were not deemed severe, and included pyrexia, abdominal pain, diarrhea, nausea and a mild rash. These adverse effects were seen in patients who were administered Idelalisib both with and without the addition of Rituximab.

Phase III results were impressive for Zydelig {Idelalisib}, showing a response rate of 81 percent. When clinical study participants received both Idelalisib and Rituximab to treat refractory chronic lymphocytic leukemia patients gleaned a 93 percent progression-free survival rate at 24 weeks. The advent of Idelalisib offers patients with these hard to treat forms of blood cancers better options for treatment and hope for tangible progression free survival. Idelalisib is also easy to administer as oral tablets which are typically taken twice daily, either with or without food. There are over 200,000 patients in the United States who suffer from relapsed follicular B-cell non-Hodgkin lymphoma, relapsed chronic lymphocytic leukemia or small lymphocytic lymphoma. This patient population is clearly in need of innovative and effective treatments.

LGM Pharma can assist clients as a provider of Idelalisib, CAS # 870281-82-6, for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

 

 

  • Share: